Menu About us Pharmaceuticals Pharmaceuticals Our Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immuno-inflammation and oncology. We are strengthening our R&D pipeline through a focus on immunology, human genetics and advanced technologies to help us deliver transformational new medicines for patients. The business generated sales of £17 billion in 2020. Our marketplace The global pharmaceuticals market is vast. The US remains a priority market for growth with other key growth areas including emerging markets and Asia Pacific regions. This trend of increasing demand is expected to continue as the world’s population grows, economies in the emerging markets become more prosperous and global changes in lifestyles affect long-term health. Our Pharmaceuticals portfolio Our portfolio is made up of innovative and established medicines and we have leading global positions in respiratory disease and HIV. We have been a leader in respiratory disease for over 40 years and have a portfolio of mature products. In recent years, we have strengthened and broadened our respiratory portfolio with the addition of new medicines including an inhaled corticosteroid (ICS) and long-acting beta2 agonist (LABA) combination, a long-acting muscarinic antagonist (LAMA) and LABA dual bronchodilator. Our HIV business is managed through ViiV Healthcare, a global specialist company in HIV that we majority own, with Pfizer and Shionogi as shareholders. ViiV Healthcare is now a leading global company in HIV and has had significant recent success with regulatory approval and industry leading launches of new medicines. ViiV Healthcare has a number of other antiretroviral medicines in clinical development. In addition to respiratory and HIV, we have a portfolio of other innovative pharmaceutical products for the treatment of conditions such as lupus, urology and anti-infectives. We also have an Established Products Portfolio (EPP) which includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business where the GSK brand is an important differentiator. The journey to discovering and developing new medicines is lengthy, expensive and subject to a high rate of failure. Learn more about our research and development. We are exploring different approaches to promote – and speed up – innovation in our labs. Having broken down the traditional, R&D model, our scientists now work in smaller units focused on specific areas of research. This encourages greater entrepreneurialism and accountability. These groups are tasked with seeking out the biological targets involved in disease and creating molecules or biopharmaceuticals that will ultimately become new medicines. We also know that we won’t discover everything inside our own labs and that we need to partner with other companies, academic institutions and research charities. We currently have research collaborations with more than 1,500 external organisations. We also recognise our responsibility to meet society’s expectations to invest in disease areas where the science is difficult or where the typical business model to reward innovation may not be relevant; one example being our antibiotics research. We are also one of the few healthcare companies researching the World Health Organization’s three priority diseases - HIV/AIDS, tuberculosis and malaria. Other business areas Vaccines We are the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. Consumer Healthcare Our world-leading Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend. RSS Other GSK websites Market website selector GSKPro for healthcare professionals GSK Study Register Quick links COVID-19 response Behind the science About us Products Careers Investors Media Research and development Responsibility Accessibility/legal Accessibility Terms of use Cookie policy Privacy notice Modern Slavery Act statement 2020 PDF - 191.4KB Sitemap Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our market selector. © 2001-2021 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. We use cookies GSK values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content.Cookie Policy Show detail ❮ OPT OUT ACCEPT ALL